TREATMENT OF RENAL CARCINOMA IN A BINTURONG (ARCTICTIS BINTURONG) WITH NEPHRECTOMY AND A TYROSINE KINASE INHIBITOR

被引:1
|
作者
Thompson, Kimberly A. [1 ]
Patterson, Jon [2 ]
Fitzgerald, Scott D. [2 ]
Needle, David [2 ,3 ]
Harrison, Tara [1 ,4 ]
机构
[1] Michigan State Univ, Coll Vet Med, 784 Wilson Rd, E Lansing, MI 48824 USA
[2] Michigan State Univ, Diagnost Ctr Populat & Anim Hlth, Coll Vet Med, 4125 Beaumont Rd, Lansing, MI 48824 USA
[3] Univ New Hampshire, New Hampshire Vet Diagnost Lab, 21 Bot Lane, Durham, NH 03824 USA
[4] North Carolina State Univ, Dept Clin Sci, 1060 William Moore Dr, Raleigh, NC 27607 USA
关键词
Arctictis binturong; binturong; nephrectomy; renal adenocarcinoma; toceranib phosphate; tyrosinekinase inhibitor; CELL CARCINOMA; HYPERCALCEMIA; CANINE;
D O I
10.1638/2015-0285.1
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
A 13-yr-old female binturong (Arctictis binturong) presented with a 1 wk history of decreased appetite. The animal was thin, with hypercalcemia (calcium 12.2 mg/dl). A right renal mass was identified on ultrasound and removed via nephrectomy. Histopathology indicated a renal adenocarcinoma. Treatment with toceranib phosphate, a tyrosine-kinase inhibitor, was initiated and well tolerated by the animal. Four months after initial diagnosis radiographs indicated metastases to the lungs and the animal was euthanized. Necropsy revealed disseminated adenocarcinoma. Although treatment did not prevent metastasis, it was minimally invasive and well tolerated by the animal with minimal side effects. Review of records at the institution revealed that the cause of death for the primary case's dam and sire was disseminated renal carcinoma. These cases suggest that there may be a hereditary component to development of renal neoplasia in binturongs. Renal carcinoma should be considered an aggressive neoplasia in binturongs with a poor prognosis.
引用
收藏
页码:1109 / 1113
页数:5
相关论文
共 50 条
  • [41] Treatment of advanced renal cell carcinoma after tyrosine kinase inhibitor therapy: first experiences with Everolimus (Afinitor®) in practice
    Johannsen, M.
    Kempkensteffen, C.
    Miller, K.
    Weikert, S.
    ONKOLOGIE, 2010, 33 : 90 - 90
  • [42] Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy
    Carvalho, Filipe L. F.
    Zheng, Chaoyi
    Witmer, Kenneth
    O'neill, John
    Lynch, John H.
    Kowalczyk, Keith J.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [43] Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy
    Filipe L. F. Carvalho
    Chaoyi Zheng
    Kenneth Witmer
    John O’neill
    John H. Lynch
    Keith J. Kowalczyk
    Scientific Reports, 9
  • [44] Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional Study
    Stroup, Sean P.
    Raheem, Omer A.
    Palazzi, Kerrin L.
    Liss, Michael A.
    Mehrazin, Reza
    Kopp, Ryan P.
    Patel, Nishant
    Cohen, Seth A.
    Park, Samuel K.
    Patterson, Anthony L.
    Kane, Christopher J.
    Millard, Frederick
    Derweesh, Ithaar H.
    UROLOGY, 2013, 81 (04) : 805 - 811
  • [45] Tyrosine kinase inhibitors in renal cell carcinoma
    Potti, A
    George, DJ
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6371S - 6376S
  • [46] Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor therapy response in renal cell carcinoma
    Gu, L.
    Liang, Q.
    Zhang, X.
    Wang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1507 - S1507
  • [47] Tyrosine Kinase Inhibitors in Advanced Renal Cell Carcinoma: The Evolving Treatment Paradigm
    Bukowski, Ronald M.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 9 - 10
  • [48] The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases
    Aytekin, Aydin
    Ciltas, Aydin
    Sahinli, Hayriye
    Benekli, Mustafa
    JOURNAL OF BUON, 2016, 21 (01): : 281 - 282
  • [49] Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
    Vasudev, Naveen S.
    Larkin, James M. G.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 333 - 342
  • [50] Discontinuation of the Tyrosine Kinase Inhibitor Sunitinib in Patients with Metastatic Renal Cell Carcinoma: A Case Series
    Neuhaus, Thomas
    Luyken, Joachim
    Stier, Sebastian
    UROLOGY JOURNAL, 2014, 11 (02) : 1494 - 1498